Radionuclide Drug Conjugate Market - Global Forecast 2026-2032

The radionuclide drug conjugate market is at a crucial inflection point, shaped by innovation in targeted therapies and improved manufacturing scalability. Senior leaders must evaluate how these advanced agents synchronize with evolving oncology strategies and operational requirements.

Market Snapshot: Radionuclide Drug Conjugate Market Growth Outlook

The Radionuclide Drug Conjugate Market is set to grow from USD 840.27 million in 2025 to USD 906.01 million in 2026, maintaining momentum with a projected CAGR of 10.77% and an anticipated value of USD 1.72 billion by 2032. This positive trajectory is propelled by the increasing adoption of precision oncology, expanding clinical application, continued capital formation, and stronger supply chain frameworks. Stakeholders are witnessing broader integration of diagnostic and therapeutic platforms within global markets, as well as deeper involvement from established healthcare networks and new entrants investing in infrastructure and expertise.

Scope & Segmentation

This analysis delivers clarity across all principal business, clinical, and operational segments forming the current radionuclide drug conjugate landscape:

Product Formats: Antibody-drug conjugates, small-molecule conjugates, and peptide-based conjugates present specific delivery and radiolabeling complexities, influencing manufacturing and clinical deployment strategies.
Radionuclide Classes: Both alpha and beta emitters are utilized based on their compatibility with various targeting vectors and requirements for different clinical indications.
Therapeutic Indications: Oncology remains the main focus, with detailed segmentation by tumor type, target antigens, and whether treatments are optimized for metastatic or localized disease.
Target Antigens: Decisions rely on mature and emerging targets, which affect the need for companion diagnostics and patient stratification initiatives within health systems.
End User Settings: Hospitals, cancer centers, and outpatient facilities each provide unique operational challenges, especially concerning workflow integration and throughput optimization.
Manufacturing Models: Centralized manufacturing with regional distribution coexists with decentralized approaches, each adapting to isotope half-life constraints and ensuring consistent delivery timelines.
Regional Markets: Coverage extends across the Americas, EMEA, and Asia-Pacific, where infrastructure maturity, regulatory paths, and adoption rates vary, influencing technology uptake and service models.

Key Takeaways

Radionuclide drug conjugates enhance the precision of targeted therapy, optimizing molecular specificity and reducing non-specific toxicity to support wider clinical adoption.
Platform innovation, especially in theranostic approaches, is moving these agents from research into scalable therapeutic solutions that meet industrial standards and market expectations.
Operational alignment between radiochemistry, logistics, and clinical workflows is fundamental, with automation and GMP-compliant quality systems emerging as decisive factors for success.
Market competition intensifies as large biopharmaceutical firms and specialized partners drive investment in vertical supply chain integration and proprietary radiochemistry technology.
Effective end-user enablement—through safety training, infrastructure development, and educational initiatives—is essential for increasing market penetration and supporting optimal patient outcomes.
Flexible sourcing and regionalized supply planning have gained importance, allowing companies to better manage uncertainties related to distribution and shifting market conditions.

Tariff Impact and Supply Chain Resilience

Anticipated changes in United States tariff policy for 2025 could affect radionuclide drug conjugate costs, largely through duties imposed on essential upstream materials and critical equipment. These financial shifts may elevate capital investment requirements and create delays in expanding physical facilities, with downstream consequences for clinical trial supply and readiness at treatment sites. As tariffs influence the cost structure of enabling components, companies may accelerate moves toward domestic sourcing, invest in stronger relationships with U.S.-based CDMOs and suppliers, and adopt dual-source procurement models. Strategic supply chain planning, alternate supplier qualification, and enhanced inventory controls are strongly recommended for stakeholders seeking to navigate this evolving landscape.

Regional Readiness

Regional differences continue to define adoption rates and market readiness. The Americas benefit from robust innovation ecosystems and site preparedness; however, reimbursement remains a complex area for administrators. Western Europe is distinguished by rapid integration of theranostic approaches within scientific networks, yet faces regulatory fragmentation at the country level. Asia-Pacific is scaling quickly in production and clinical capabilities, investing in radiopharmacy infrastructure and demonstrating strong growth prospects as delivery networks mature further.

Methodology & Data Sources

This report utilizes a triangulated methodology, combining secondary research from scientific publications, trial registries, patents, and company filings with primary interviews involving developers, clinicians, physicists, and supply chain experts. Analytical validation supports credible findings, ensuring each insight aligns with operational and clinical realities.

Why This Report Matters

Connects scientific choices to actionable commercial and operational strategies in the radionuclide drug conjugate market, enabling senior leaders to plan confidently for market evolution.
Delivers strategic insight into segmentation and supply chain drivers, supporting informed positioning against changing regulatory, policy, and infrastructure environments.
Helps guide investment and partnership decisions by mapping risk and opportunity throughout the product lifecycle, supporting resilient growth.

Conclusion

Success in the radionuclide drug conjugate sector now relies on seamless execution across manufacturing, supply, and clinical adoption. Organizations that align these elements early will strengthen their impact and competitiveness as the market continues to evolve.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Radionuclide Drug Conjugate Market, by Emission Type

8.1. Alpha Emitter
8.2. Beta Emitter

9. Radionuclide Drug Conjugate Market, by Targeting Molecule

9.1. Monoclonal Antibody
9.2. Peptide
9.3. Small Molecule

10. Radionuclide Drug Conjugate Market, by Indication

10.1. Neuroendocrine Tumor
10.2. Prostate Cancer

11. Radionuclide Drug Conjugate Market, by Distribution Channel

11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy

12. Radionuclide Drug Conjugate Market, by End User

12.1. Hospital
12.1.1. Academic Hospital
12.1.2. Community Hospital
12.2. Research Institute
12.3. Specialty Clinic

13. Radionuclide Drug Conjugate Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. Radionuclide Drug Conjugate Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Radionuclide Drug Conjugate Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States Radionuclide Drug Conjugate Market
17. China Radionuclide Drug Conjugate Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Bayer AG
18.6. Curium Pharma S.A.
18.7. DongCheng Pharmaceutical Group
18.8. Eckert & Ziegler Strahlen- und Medizintechnik AG
18.9. Ion Beam Applications S.A.
18.10. Jubilant Pharmova Limited
18.11. Lantheus Holdings, Inc.
18.12. Nordion Inc.
18.13. Novartis AG
18.14. Point Biopharma Solutions, Inc.
18.15. Telix Pharmaceuticals Limited

List of Figures

FIGURE 1. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ALPHA EMITTER, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ALPHA EMITTER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ALPHA EMITTER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY BETA EMITTER, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY BETA EMITTER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY BETA EMITTER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY NEUROENDOCRINE TUMOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY NEUROENDOCRINE TUMOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY NEUROENDOCRINE TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 55. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 56. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 57. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 58. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 59. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 60. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 61. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 63. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 64. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 65. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 66. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 68. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 70. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 71. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 72. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 73. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. LATIN AMERICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 82. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 84. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 85. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 86. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 87. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 88. EUROPE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 89. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 91. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 92. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 93. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 94. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. MIDDLE EAST RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 96. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 98. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 99. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 100. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 101. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 113. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 114. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 115. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 117. ASEAN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 118. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 120. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 121. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 122. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. GCC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 132. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 134. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 135. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 136. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. BRICS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 139. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 141. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 142. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 143. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 144. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. G7 RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 146. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 148. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 149. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 150. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. NATO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 155. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 156. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 158. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 159. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 161. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 162. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2032 (USD MILLION)
TABLE 163. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2032 (USD MILLION)
TABLE 164. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 165. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. CHINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Radionuclide Drug Conjugate market report include:

Bayer AG
Curium Pharma S.A.
DongCheng Pharmaceutical Group
Eckert & Ziegler Strahlen- und Medizintechnik AG
Ion Beam Applications S.A.
Jubilant Pharmova Limited
Lantheus Holdings, Inc.
Nordion Inc.
Novartis AG
Point Biopharma Solutions, Inc.
Telix Pharmaceuticals Limited

Table Information

Report Attribute	Details
No. of Pages	196
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 906.01 Million
Forecasted Market Value ( USD ) by 2032	$ 1720 Million
Compound Annual Growth Rate	10.7%
Regions Covered	Global
No. of Companies Mentioned	12

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3511EUR$3,939USD£3,045GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3787EUR$4,249USD£3,285GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5133EUR$5,759USD£4,452GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6212EUR$6,969USD£5,387GBP

Market Snapshot: Radionuclide Drug Conjugate Market Growth Outlook

Scope & Segmentation

Key Takeaways

Tariff Impact and Supply Chain Resilience

Regional Readiness

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Antibody Oligonucleotide Conjugates Drug Market - Global Forecast 2026-2032

Pediatric Drugs and Vaccines - Global Strategic Business Report

PDC Drug Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2025

Rare Diseases Treatment Market - Global Forecast 2025-2032